A Phase 2 interventional study of certepetide and Durvalumab in Cholangiocarcinoma, Gallbladder Cancer and Gallbladder Carcinoma, sponsored by Lisata Therapeutics, Inc.. Completed at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Lisata Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing cisplatin in Cholangiocarcinoma — 11 open to participants now, 12 under way, 3 of them phase 3. Cisplatin · Cholangiocarcinoma.
Among the 31 studies testing cisplatin in Cholangiocarcinoma, this one is the 11th largest by enrollment, is one of 3 that started in 2023, is one of 19 in phase 2, and was the 21st registered.
825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.
Browse Cholangiocarcinoma studies →11 of the 31 studies testing cisplatin in Cholangiocarcinoma are open now, in 4 countries. Recruiting first, the newest first:
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
Amsterdam UMC, location VUmc · Sites in Netherlands
Ages 18+
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →
Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 24 · Phase 3 5
First in 2002; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is above the median of 50 across 624 interventional studies indexed under Cholangiocarcinoma.
Median enrollment 33 across the 31 interventional studies. Of the 16 that completed or were terminated, 10 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 31 have an industry lead sponsor. The 10 most frequent:
Lisata Therapeutics, Inc. is the lead sponsor of 17 studies on the registry; none are open to participants now.
Lisata Therapeutics, Inc. has 1 study filed under Cholangiocarcinoma — fewer than ten, so there is no comparison to draw.
4 of the studies testing cisplatin in Cholangiocarcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05655949Beth Israel Deaconess Medical CenterY-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio | 2026-12-01 |
| NCT06721286Tianjin Medical University Cancer Institute and HospitalToripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma | 2026-12-31 |
| NCT06280508Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityChemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer | 2027-03-31 |
| NCT07570849Shanghai Zhongshan HospitalChidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies testing cisplatin in Cholangiocarcinoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with previously untreated cholangiocarcinoma or those that have progressed after first-line treatment for cholangiocarcinoma.
The main questions it aims to answer are:
This is a Phase 2a, double-blind, placebo-controlled, multi-center, randomized study of LSTA1 when added to standard of care (SoC) versus SoC alone in patients with advanced solid tumors. The study will include patients with previously untreated cholangiocarcinoma or those that have progressed after first-line treatment for cholangiocarcinoma.
The study will consist of a screening period, a run-in period, a treatment period, an end-of-treatment follow-up visit, and a long-term follow up period.
Participants who provide informed consent will be screened for eligibility within 28 days prior to beginning the study treatment run-in period. Once eligibility is confirmed, participants will be randomized to one of the two treatment groups (SoC + placebo vs. SoC + LSTA1).
During the 3-day run-in period, participants will only receive the LSTA1 or placebo components of their randomized treatment regimen. After the 3-day run-in, Cycle 1 of treatment will commence. Tumor scans will be performed every 8 weeks (56 days ± 7 days) while on treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with either of the following:
Exclusion Criteria:
Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results, including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: certepetide · Drug: Durvalumab · Drug: Cisplatin · Drug: Gemcitabine
Drug: certepetide · Drug: FOLFOX regimen
Drug: Durvalumab · Drug: Cisplatin · Drug: Gemcitabine · Drug: Placebo
Drug: FOLFOX regimen · Drug: Placebo
LSTA1 3.2 mg/kg given as a slow IV push over 1 minute when standard treatment(s) are given
Also known as: CEND-1, LSTA1
1500 mg of durvalumab IV administered over 1 hour every 21 days for 8 cycles then every 28 days for additional cycles
Also known as: Imfinzi
cisplatin 25 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
gemcitabine 1000 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
The following will be given every 14 days: * oxaliplatin 85 mg/m² and l-folinic acid 200 mg/m² or d,l-folinic acid 400 mg/m² concurrently, as a 2-hour IV infusion * fluorouracil (5-FU) 400 mg/m² will be given as an IV bolus over 5 minutes * fluorouracil (5-FU) 2400 mg/m² will be administered over 46 hours (via home-infusion pump)
Also known as: Oxaliplatin, Folinic acid, Fluorouracil
Placebo given as a slow IV push over 1 minute when standard treatment(s) are given
Number of Subjects Experiencing Any Adverse Event
The National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE) will be used to grade the intensity of adverse events throughout the study
Time frame: From time of consent until 30 days after treatment discontinuation, up to 18 months
Subjects were enrolled from May 2023 to February 2025. All enrolled subjects were from sites in the United States.
| Milestone | LSTA1 Arm for Untreated Cholangiocarcinoma | LSTA1 Arm for Second-Line Cholangiocarcinoma | Placebo Arm for Untreated Cholangiocarcinoma | Placebo Arm for Second-Line Cholangiocarcinoma |
|---|---|---|---|---|
| Started | 23 | 11 | 21 | 11 |
| Completed | 23 | 11 | 21 | 11 |
| Not completed | 0 | 0 | 0 | 0 |
The National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE) will be used to grade the intensity of adverse events throughout the study
| Participants | LSTA1 Arm for Untreated Cholangiocarcinoma | LSTA1 Arm for Second-Line Cholangiocarcinoma | Placebo Arm for Untreated Cholangiocarcinoma | Placebo Arm for Second-Line Cholangiocarcinoma |
|---|---|---|---|---|
| Number of Subjects Experiencing Any Adverse Event | 23 | 11 | 21 | 11 |
Collected over Adverse event data were collected from time of consent, up to 18 months, or until patient death. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LSTA1 Arm for Untreated Cholangiocarcinoma | 12/23 (52.2%) | 10/23 (43.5%) | 23/23 (100%) |
| LSTA1 Arm for Second-Line Cholangiocarcinoma | 4/11 (36.4%) | 3/11 (27.3%) | 11/11 (100%) |
| Placebo Arm for Untreated Cholangiocarcinoma | 10/21 (47.6%) | 12/21 (57.1%) | 20/21 (95.2%) |
| Placebo Arm for Second-Line Cholangiocarcinoma | 2/11 (18.2%) | 4/11 (36.4%) | 11/11 (100%) |
| Event | LSTA1 Arm for Untreated Cholangiocarcinoma | LSTA1 Arm for Second-Line Cholangiocarcinoma | Placebo Arm for Untreated Cholangiocarcinoma | Placebo Arm for Second-Line Cholangiocarcinoma |
|---|---|---|---|---|
| SepsisInfections and infestations | 1/23 | 0/11 | 2/21 | 0/11 |
| FatigueGeneral disorders | 0/23 | 0/11 | 2/21 | 0/11 |
| ColitisGastrointestinal disorders | 0/23 | 1/11 | 0/21 | 0/11 |
| Blood bilirubin increasedInvestigations | 1/23 | 0/11 | 0/21 | 1/11 |
| Platelet count decreasedInvestigations | 1/23 | 1/11 | 1/21 | 1/11 |
| NeutropeniaBlood and lymphatic system disorders | 0/23 | 0/11 | 0/21 | 1/11 |
| Bile duct stenosisHepatobiliary disorders | 0/23 | 0/11 | 0/21 | 1/11 |
| FractureInjury, poisoning and procedural complications | 0/23 | 0/11 | 0/21 | 1/11 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/23 | 1/11 | 0/21 | 0/11 |
| DeathGeneral disorders | 0/23 | 0/11 | 0/21 | 1/11 |
| Event | LSTA1 Arm for Untreated Cholangiocarcinoma | LSTA1 Arm for Second-Line Cholangiocarcinoma | Placebo Arm for Untreated Cholangiocarcinoma | Placebo Arm for Second-Line Cholangiocarcinoma |
|---|---|---|---|---|
| FatigueGeneral disorders | 12/23 | 6/11 | 14/21 | 4/11 |
| Decreased appetiteMetabolism and nutrition disorders | 4/23 | 7/11 | 4/21 | 2/11 |
| ConstipationGastrointestinal disorders | 11/23 | 3/11 | 12/21 | 5/11 |
| NauseaGastrointestinal disorders | 6/23 | 5/11 | 11/21 | 4/11 |
| Platelet count decreasedInvestigations | 7/23 | 5/11 | 6/21 | 3/11 |
| AnaemiaBlood and lymphatic system disorders | 10/23 | 2/11 | 9/21 | 2/11 |
| Neutrophil count decreasedInvestigations | 8/23 | 4/11 | 9/21 | 4/11 |
| DiarrhoeaGastrointestinal disorders | 6/23 | 3/11 | 2/21 | 4/11 |
| ParaesthesiaNervous system disorders | 4/23 | 4/11 | 1/21 | 3/11 |
| White blood cell count decreasedInvestigations | 4/23 | 4/11 | 6/21 | 3/11 |
| Age, Continuous(years) | LSTA1 Arm for Untreated Cholangiocarcinoma | LSTA1 Arm for Second-Line Cholangiocarcinoma | Placebo Arm for Untreated Cholangiocarcinoma | Placebo Arm for Second-Line Cholangiocarcinoma | Total |
|---|---|---|---|---|---|
| Mean | 63.2 ± 9.74 | 62.6 ± 9.99 | 63.5 ± 9.67 | 62.5 ± 8.66 | 62.9 ± 9.52 |
| Sex: Female, Male(Participants) | LSTA1 Arm for Untreated Cholangiocarcinoma | LSTA1 Arm for Second-Line Cholangiocarcinoma | Placebo Arm for Untreated Cholangiocarcinoma | Placebo Arm for Second-Line Cholangiocarcinoma | Total |
|---|---|---|---|---|---|
| Female | 10 | 6 | 9 | 7 | 32 |
| Male | 13 | 5 | 12 | 4 | 34 |
| Ethnicity (NIH/OMB)(Participants) | LSTA1 Arm for Untreated Cholangiocarcinoma | LSTA1 Arm for Second-Line Cholangiocarcinoma | Placebo Arm for Untreated Cholangiocarcinoma | Placebo Arm for Second-Line Cholangiocarcinoma | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 4 | 2 | 9 |
| Not Hispanic or Latino | 19 | 9 | 15 | 9 | 52 |
| Unknown or Not Reported | 3 | 0 | 2 | 0 | 5 |
| Race (NIH/OMB)(Participants) | LSTA1 Arm for Untreated Cholangiocarcinoma | LSTA1 Arm for Second-Line Cholangiocarcinoma | Placebo Arm for Untreated Cholangiocarcinoma | Placebo Arm for Second-Line Cholangiocarcinoma | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 2 | 1 | 1 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 0 | 0 | 2 |
| White | 19 | 8 | 19 | 10 | 56 |
| More than one race | 0 | 1 | 0 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
| Region of Enrollment(participants) | LSTA1 Arm for Untreated Cholangiocarcinoma | LSTA1 Arm for Second-Line Cholangiocarcinoma | Placebo Arm for Untreated Cholangiocarcinoma | Placebo Arm for Second-Line Cholangiocarcinoma | Total |
|---|---|---|---|---|---|
| United States | 23 | 11 | 21 | 11 | 66 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2023 to primary completion in Apr 2026, 34 months.
Results were first posted in May 2026, 1 month after primary completion.
Of 173 phase 2 interventional studies under Cholangiocarcinoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 34 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Certepetide · Cisplatin · Gemcitabine · Folfox protocol
Lisata Therapeutics, Inc.